194 related articles for article (PubMed ID: 36351654)
1. [Current status and future perspective of CAR T-cell therapy for acute myeloid leukemia].
Nakazawa Y
Rinsho Ketsueki; 2022; 63(10):1446-1453. PubMed ID: 36351654
[TBL] [Abstract][Full Text] [Related]
2. [A first-in-human clinical trial of piggyBac transposon-mediated GMR CAR-T cells against CD116-positive acute myeloid leukemia and juvenile myelomonocytic leukemia].
Nakazawa Y
Rinsho Ketsueki; 2022; 63(7):776-781. PubMed ID: 35922947
[TBL] [Abstract][Full Text] [Related]
3. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
5. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
[TBL] [Abstract][Full Text] [Related]
6. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
[TBL] [Abstract][Full Text] [Related]
8. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
Wang XY; Bian MR; Lin GQ; Yu L; Zhang YM; Wu DP
Eur J Haematol; 2024 Jan; 112(1):83-93. PubMed ID: 37712633
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
Wang X; Zhang Y; Xue S
Ann Hematol; 2024 Jun; 103(6):1843-1857. PubMed ID: 38381173
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.
Zhang H; Bu C; Peng Z; Li G; Zhou Z; Ding W; Zheng Y; He Y; Hu Z; Pei K; Luo M; Li C
Leukemia; 2022 Nov; 36(11):2596-2604. PubMed ID: 36151140
[TBL] [Abstract][Full Text] [Related]
11. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Pratap S; Zhao ZJ
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
[TBL] [Abstract][Full Text] [Related]
12. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H; Navarro-Bailón A; Maucher M; Frenz S; Verbruggen C; Yeguas A; Vidriales MB; González M; Rial Saborido J; Kraus S; Mestermann K; Thomas S; Bonig H; Luu M; Monjezi R; Mougiakakos D; Sauer M; Einsele H; Hudecek M
Blood; 2021 Nov; 138(19):1830-1842. PubMed ID: 34289026
[TBL] [Abstract][Full Text] [Related]
13. Prospect of CAR T-cell therapy in acute myeloid leukemia.
Badar T; Manna A; Gadd ME; Kharfan-Dabaja MA; Qin H
Expert Opin Investig Drugs; 2022 Feb; 31(2):211-220. PubMed ID: 35051347
[TBL] [Abstract][Full Text] [Related]
14. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
15. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
[TBL] [Abstract][Full Text] [Related]
17. Mutated GM-CSF-based CAR-T cells targeting CD116/CD131 complexes exhibit enhanced anti-tumor effects against acute myeloid leukaemia.
Hasegawa A; Saito S; Narimatsu S; Nakano S; Nagai M; Ohnota H; Inada Y; Morokawa H; Nakashima I; Morita D; Ide Y; Matsuda K; Tashiro H; Yagyu S; Tanaka M; Nakazawa Y
Clin Transl Immunology; 2021; 10(5):e1282. PubMed ID: 33976880
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
[TBL] [Abstract][Full Text] [Related]
19. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH; Murad J; Werner L; Daley H; Trebeden-Negre H; Gicobi JK; Schmucker A; Reder J; Sentman CL; Gilham DE; Lehmann FF; Galinsky I; DiPietro H; Cummings K; Munshi NC; Stone RM; Neuberg DS; Soiffer R; Dranoff G; Ritz J; Nikiforow S
Cancer Immunol Res; 2019 Jan; 7(1):100-112. PubMed ID: 30396908
[TBL] [Abstract][Full Text] [Related]
20. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
Caulier B; Joaquina S; Gelebart P; Dowling TH; Kaveh F; Thomas M; Tandaric L; Wernhoff P; Katyayini NU; Wogsland C; Gjerstad ME; Fløisand Y; Kvalheim G; Marr C; Kobold S; Enserink JM; Gjertsen BT; McCormack E; Inderberg EM; Wälchli S
Cell Rep Med; 2024 Jun; 5(6):101572. PubMed ID: 38754420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
